Page 11234..1020..»

Category Archives: Ulcerative Colitis

Living with IBD: What coping strategies are most effective? – News-Medical.Net

Posted: Published on March 15th, 2024

In a recent review article published in the Journal of Clinical Medicine, researchers summarized the results of a systematic review that explored the impact of different coping strategies for people living with inflammatory bowel disease (IBD). Study:Coping Strategies and Inflammatory Bowel Disease: A Narrative Review. Continue reading

Posted in Ulcerative Colitis | Comments Off on Living with IBD: What coping strategies are most effective? – News-Medical.Net

Etrasimod approved to treat patients over the age of 16 with ulcerative colitis – GOV.UK

Posted: Published on March 15th, 2024

Ulcerative colitis is a long-term condition where the colonand rectum become inflamed. Smallulcers can develop onthe colons liningand can bleed and produce pus. The main symptoms of ulcerative colitis are recurring diarrhoea, which may contain blood, mucus or pus, stomach pain and increased stool frequency Continue reading

Posted in Ulcerative Colitis | Comments Off on Etrasimod approved to treat patients over the age of 16 with ulcerative colitis – GOV.UK

Clinical outcomes of patients with remitting ulcerative colitis after discontinuation of indigo naturalis | Scientific Reports – Nature.com

Posted: Published on March 15th, 2024

Study design and patient population A single-center retrospective study design was used to investigate the follow-up of patients treated with IN between 2015 and 2020. Powdered IN (Fujian Province, China) was purchased from Uchidawakanyaku Ltd. (Tokyo, Japan) Continue reading

Posted in Ulcerative Colitis | Comments Off on Clinical outcomes of patients with remitting ulcerative colitis after discontinuation of indigo naturalis | Scientific Reports – Nature.com

Pfizers Velsipity receives MHRA and NICE authorisations to treat ulcerative colitis – PMLiVE

Posted: Published on March 15th, 2024

Pfizers once-daily S1P receptor modulator Velsipity (etrasimod) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat moderately-to-severely active ulcerative colitis (UC). The drug has been concurrently recommended by the National Institute for Health and Care Excellence (NICE) for use in patients aged 16 years and older who have had an inadequate response, lost response or been intolerant to conventional therapy or biological treatment. Affecting approximately 300,000 people in the UK, UC is a chronic, immune-mediated condition where the colon and rectum become inflamed, causing symptoms such as frequent diarrhoea, bowel urgency, rectal bleeding, abdominal pain, fatigue, fever and anaemia. Continue reading

Posted in Ulcerative Colitis | Comments Off on Pfizers Velsipity receives MHRA and NICE authorisations to treat ulcerative colitis – PMLiVE

Anti-integrin v6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor … – Nature.com

Posted: Published on March 15th, 2024

Patients This was a retrospective study targeting patients with ICI-induced colitis who had undergone colonoscopy at the onset of the disease at Kyoto University Hospital, affiliated hospitals, and Kindai University Faculty of Medicine between April 2018 and April 2023. All but one patient (Case 1) was treated with only ICI treatment. ICI-induced colitis was defined as diarrhea or bloody stools following ICI administration and/or with histological evaluation [5]. Continue reading

Posted in Ulcerative Colitis | Comments Off on Anti-integrin v6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor … – Nature.com

Etrasimod (Velsipity) recommended as a treatment option for Ulcerative Colitis in England – Crohn’s & Colitis UK

Posted: Published on March 15th, 2024

NICE is the organisation that decides whether treatments should be available on the NHS in England. Wales and Northern Ireland usually follow NICE decisions too. In Scotland, these decisions are made by the Scottish Medicines Consortium (SMC). Continue reading

Posted in Ulcerative Colitis | Comments Off on Etrasimod (Velsipity) recommended as a treatment option for Ulcerative Colitis in England – Crohn’s & Colitis UK

I’m a Frequent Traveler With Crohn’s DiseaseHere Are My Packing List Non-Negotiables – Cond Nast Traveler

Posted: Published on March 15th, 2024

When I was a kid, I took lots of tripsto the bathroom. Continue reading

Posted in Ulcerative Colitis | Comments Off on I’m a Frequent Traveler With Crohn’s DiseaseHere Are My Packing List Non-Negotiables – Cond Nast Traveler

Pfizer’s Velsipity heading for NHS use in ulcerative colitis – pharmaphorum

Posted: Published on March 15th, 2024

Up to 25,000 people with ulcerative colitis (UC) in England could be in line for treatment with Pfizers once-daily oral therapy Velsipity, after NICE recommended its use by the NHS. The new guidance emerged on the same day that Velsipity (etrasimod) was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as a treatment for moderately to severely active UC, a few weeks after it was cleared by the European Commission. Continue reading

Posted in Ulcerative Colitis | Comments Off on Pfizer’s Velsipity heading for NHS use in ulcerative colitis – pharmaphorum

25000 people to benefit after NICE recommends new ulcerative colitis treatment – NICE

Posted: Published on March 15th, 2024

Thousands of people could be set to benefit after NICE today (Monday, 11 March) recommended a new one-a-day pill as an option for treating severe ulcerative colitis. NICEs final guidance on etrasimod (also known as Velsipity and made by Pfizer) is being published on the same day that the treatment was granted a licence by the Medicines and Healthcare Products Regulatory Agency (MHRA). Just over 25,000 people in England are eligible to receive the new treatment, which was evaluated using a simpler technology appraisal process. Continue reading

Posted in Ulcerative Colitis | Comments Off on 25000 people to benefit after NICE recommends new ulcerative colitis treatment – NICE

NICE recommends new ulcerative colitis treatment for NHS use – Nursing Times

Posted: Published on March 15th, 2024

A new once-a-day pill has been recommended as an option for treating severe ulcerative colitis in England, with thousands of patients set to be eligible. The National Institute for Health and Care Excellence (NICE) has published final guidance backing the treatment etrasimod (Velsipity) We are determined to continue getting the best care to patients fast Helen Knight The move, on Monday, came on the same day that etrasimod was granted a licence by the Medicines and Healthcare Products Regulatory Agency (MHRA). Continue reading

Posted in Ulcerative Colitis | Comments Off on NICE recommends new ulcerative colitis treatment for NHS use – Nursing Times

Page 11234..1020..»